# Genomas

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genomas

- Industry: Healthcare IT
- Headquarters: Hartford, US
- Website: www.genomas.net
- Total disclosed funding: $2.5M
- Latest round: Series C (Sep 25, 2007)
- Investors on record: 3

## About

Genomas, Inc. specializes in genomic medicine, providing solutions that integrate genetic insights into healthcare practices to enhance patient outcomes through personalized treatment plans.Founded in 2003, Genomas, Inc. operates from Hartford, US, focusing on genomic medicine. In September 2016, the company underwent a Trade Sale, being acquired by Rennova Health, Inc. for USD 1.75 mn, marking a significant pivot in its business strategy as it transitioned under new ownership. Genomas has completed a total of 9 deals, solidifying its position in the genomics sector.Genomas, Inc. offers a range of innovative digital solutions centered around genomic medicine, focusing on personalized healthcare by integrating genetic data into clinical practices. Its core offerings include genetic testing services and software solutions to aid healthcare providers in developing tailored treatment plans. The end users primarily consist of healthcare professionals and institutions aiming to enhance their patient care through genetic insights. The company strategically serves markets across the US and various international regions, ensuring its services meet diverse healthcare needs.Genomas, Inc. generates revenue through a structured model involving fees for genetic testing services and subscription-based access to its digital tools for healthcare providers. Clients engage with the firm via its online platform, selecting from various service plans, including one-time tests and ongoing subscription services. The integration of reliable genetic analysis and personalized medicine has established steady revenue streams. Collaborations with healthcare providers further enhance its market reach, contributing to the firm's financial stability.Following its acquisition by Rennova Health, Inc. in September 2016, Genomas, Inc. plans to leverage its recent funding to enhance its product offerings and expand into new geographic markets. The company is currently developing advanced genetic testing products aimed for release in 2024, which will further enrich its service portfolio. Additionally, Genomas targets expansion into European and Asian markets by the end of 2025, capitalizing on the growing demand for personalized medicine solutions. The funding from the Trade Sale will support these initiatives by facilitating product development and market entry strategies.

## Funding rounds

- Series C, Sep 25, 2007, $2.5M — Miradero Capital Partners, Floodgate, Hartford Hospital

## Investors

- Miradero Capital Partners (https://capitalatlas.ai/funds/miradero-capital-partners) — Series C
- Floodgate (https://capitalatlas.ai/funds/floodgate) — Series C
- Hartford Hospital — Series C